Category: 76176-87-9

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.76176-87-9,Thiomorpholine-1-oxide hydrochloride,as a common compound, the synthetic route is as follows.

To a solution of compound 1 (21.0 mg, 0.0467 mmol, 1.0 eq) in DMF (1 ml_) was added A/,A/-diisopropylethylamine (32.6 pL, 0.187 mmol, 4.0 eq), HATU (26.7 mg, 0.0701 mmol, 1.5 eq) and thiomorpholine-1 -oxide hydrochloride (2) (14.6 mg, 0.0935 mmol, 2.0 eq). The reaction was stirred at room temperature for 17.5 h then diluted with EtOAc (10 ml_), washed with 1 M HCI (2 x 10 ml_) and brine (10 ml_), dried over MgS04, filtered and concentrated in vacuo. Purification by silica gel chromatography using hexane/EtOAc/MeOH (1 :0:0 – 0:1 :0 – 0:9: 1 ) yielded compound FD as a white solid (17.6 mg, 68%). (1239) LCMS (ES): Found 550.9 [M+Hf. (1240) 1H NMR (300MHz, DMSO-cf6), d: 8.88 (d, J=1.3 Hz, 1 H), 8.45 (dd, J=2.6, 1.5 Hz, 1 H), 8.36 (d, J=2.6 Hz, 1 H), 7.85 (d, J=9.4 Hz, 1 H), 7.81 (d, J=9.4 Hz, 1 H), 7.75 (d, J=3.8 Hz, 1 H), 7.32 (d, J=3.8 Hz, 1 H), 5.72-5.80 (m, 2H), 4.34-4.48 (m, 1 H), 3.89-4.06 (m, 2H), 3.66-3.84 (m, 1 H), 2.75-3.1 1 (m, 4H). (1241) 19F NMR (282MHz, DMSO-cf6), d: -64.79 (s, 3F).

76176-87-9 Thiomorpholine-1-oxide hydrochloride 20441479, aThiomorpholine compound, is more and more widely used in various.

Reference£º
Patent; KARUS THERAPEUTICS LIMITED; SHUTTLEWORTH, Stephen Joseph; GATLAND, Alice Elizabeth; FINNEMORE, Daniel John; ALEXANDER, Rikki Peter; SILVA, Franck; CECIL, Alexander; (233 pag.)WO2019/166824; (2019); A1;,
Thiomorpholine – Wikipedia
Thiomorpholine | C4H9NS – PubChem

76176-87-9, Thiomorpholine-1-oxide hydrochloride is a Thiomorpholine compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

To a solution of thiomorpholine 1-oxide hydrochloride (140 mg) and triethylamine (0.125 mL) in N,N-dimethylformamide (15 mL) were added [2-(7-methyl-5-{[6-(methylsulfonyl)pyridin-3-yl]oxy}-1H-indol-2-yl)-4,5-dihydro-1,3-thiazol-5-yl]acetic acid (200 mg), 1-hydroxybenzotriazole (121 mg) and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (172 mg) under ice-cooling, and the mixture was stirred under ice-cooling and then at room temperature for 15 hr. Water was added to the reaction solution, and the mixture was extracted with ethyl acetate. The organic layer was washed with aqueous sodium hydrogen carbonate solution and saturated brine, dried over magnesium sulfate, filtered and concentrated under reduced pressure. The obtained residue was subjected to silica gel column chromatography (ethyl acetate:methanol = 100:0 to 75:25, volume ratio), and the obtained pale-yellow crystals were recrystallized from ethyl acetate-hexane to give the title compound (104 mg, yield 42%) as colorless crystals. melting point 157-160C. MS 547 (MH+).

The synthetic route of 76176-87-9 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; Takeda Pharmaceutical Company Limited; EP2371826; (2011); A1;,
Thiomorpholine – Wikipedia
Thiomorpholine | C4H9NS – PubChem